Media
-
Nov 9, 2020The Scottish Medicines Consortium (SMC) enables access to volanesorsen, a treatment for adults with familial chylomicronaemia syndrome (FCS)
LONDON, UK, 9 November 2020 – Akcea Therapeutics, a wholly owned subsidiary of Ionis Pharmaceuticals, Inc. (NASDAQ: IONS), announced today that the Scottish Medicines Consortium (SMC) has...
-
Nov 6, 2020Ionis and Akcea recognize FCS Awareness Day with global community efforts to celebrate unsung heroes
BOSTON and CARLSBAD, Calif., November 6, 2020 – Ionis Pharmaceuticals (NASDAQ: IONS) and its wholly owned subsidiary, Akcea Therapeutics, today recognize the 3rd annual Familial Chylomicronemia...
-
Nov 3, 2020
Ionis Pharmaceuticals, Inc. (NASDAQ: IONS) and its wholly owned subsidiary Akcea Therapeutics, Inc., today announced that Pfizer Inc. (NYSE: PFE) has initiated a Phase 2b study of vupanorsen...
-
Oct 30, 2020
Ionis Pharmaceuticals, Inc. (NASDAQ: IONS) and its wholly owned subsidiary, Akcea Therapeutics, received the Prix Galien USA Award for the Best Biotechnology Product in 2020 in recognition of...
-
Oct 12, 2020Transaction creates a stronger, more efficient company
CARLSBAD, Calif., October 12, 2020 / PRNewswire/ – Ionis Pharmaceuticals, Inc. (NASDAQ: IONS) today announced the successful completion of its transaction to acquire 100% ownership of Akcea...